company background image
OSL

OncoSil Medical ASX:OSL Stock Report

Last Price

AU$0.036

Market Cap

AU$35.7m

7D

-16.3%

1Y

-36.8%

Updated

27 Jun, 2022

Data

Company Financials +
OSL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

OSL Stock Overview

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia.

OncoSil Medical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OncoSil Medical
Historical stock prices
Current Share PriceAU$0.036
52 Week HighAU$0.081
52 Week LowAU$0.033
Beta-0.050
1 Month Change-33.33%
3 Month Change-7.69%
1 Year Change-36.84%
3 Year Change-34.54%
5 Year Change-64.00%
Change since IPO-82.00%

Recent News & Updates

May 24
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

OSLAU Life SciencesAU Market
7D-16.3%-5.3%1.4%
1Y-36.8%-43.4%-11.3%

Return vs Industry: OSL exceeded the Australian Life Sciences industry which returned -43.4% over the past year.

Return vs Market: OSL underperformed the Australian Market which returned -11.3% over the past year.

Price Volatility

Is OSL's price volatile compared to industry and market?
OSL volatility
OSL Average Weekly Movement24.3%
Life Sciences Industry Average Movement15.5%
Market Average Movement9.7%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: OSL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: OSL's weekly volatility has increased from 14% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aNigel Langehttps://www.oncosil.com.au

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013.

OncoSil Medical Fundamentals Summary

How do OncoSil Medical's earnings and revenue compare to its market cap?
OSL fundamental statistics
Market CapAU$35.68m
Earnings (TTM)-AU$11.38m
Revenue (TTM)AU$1.29m

27.9x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OSL income statement (TTM)
RevenueAU$1.29m
Cost of RevenueAU$1.27m
Gross ProfitAU$19.84k
Other ExpensesAU$11.40m
Earnings-AU$11.38m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.011
Gross Margin1.54%
Net Profit Margin-884.84%
Debt/Equity Ratio0%

How did OSL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is OSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OSL?

Other financial metrics that can be useful for relative valuation.

OSL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue22.9x
Enterprise Value/EBITDA-2.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OSL's PS Ratio compare to its peers?

OSL PS Ratio vs Peers
The above table shows the PS ratio for OSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average22.9x
CTE Cryosite
2.9xn/aAU$31.7m
BPH BPH Energy
57.5xn/aAU$7.6m
PIQ Proteomics International Laboratories
30.4xn/aAU$84.6m
EZZ EZZ Life Science Holdings
0.8xn/aAU$12.6m
OSL OncoSil Medical
27.9x6.9%AU$35.7m

Price-To-Sales vs Peers: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the peer average (22.9x).


Price to Earnings Ratio vs Industry

How does OSL's PE Ratio compare vs other companies in the Global Life Sciences Industry?

Price-To-Sales vs Industry: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the Global Life Sciences industry average (5.3x)


Price to Sales Ratio vs Fair Ratio

What is OSL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OSL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27.9x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).


Share Price vs Fair Value

What is the Fair Price of OSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OSL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OSL's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSL's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is OncoSil Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-6.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OSL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OSL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OSL's revenue (6.9% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: OSL's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OSL is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has OncoSil Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OSL is currently unprofitable.

Growing Profit Margin: OSL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OSL is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare OSL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.5%).


Return on Equity

High ROE: OSL has a negative Return on Equity (-180.83%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is OncoSil Medical's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OSL's short term assets (A$7.5M) exceed its short term liabilities (A$1.4M).

Long Term Liabilities: OSL's short term assets (A$7.5M) exceed its long term liabilities (A$234.2K).


Debt to Equity History and Analysis

Debt Level: OSL is debt free.

Reducing Debt: OSL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OSL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.3% each year


Discover healthy companies

Dividend

What is OncoSil Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OSL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Nigel Lange

1.42yrs

Tenure

AU$963,672

Compensation

Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...


CEO Compensation Analysis

Compensation vs Market: Nigel's total compensation ($USD669.77K) is above average for companies of similar size in the Australian market ($USD288.24K).

Compensation vs Earnings: Insufficient data to compare Nigel's compensation with company performance.


Leadership Team

Experienced Management: OSL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: OSL's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.


Top Shareholders

Company Information

OncoSil Medical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: OncoSil Medical Limited
  • Ticker: OSL
  • Exchange: ASX
  • Founded: 2005
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$35.685m
  • Shares outstanding: 991.24m
  • Website: https://www.oncosil.com.au

Location

  • OncoSil Medical Limited
  • 15 Blue Street
  • Suite 503
  • North Sydney
  • New South Wales
  • 2060
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.